Indaptus Therapeutics, Inc.
INDP Nasdaq
SEC CIK 1857044
Follow Indaptus Therapeutics
Weekly email: filings, results
Net income
−$1M
+64.7% vs same quarter last year
EPS, diluted
−$0.01
+99.7% vs same quarter last year
Operating cash flow
−$1.4M
+44% vs same quarter last year
Operating income
−$1.1M
+57.1% vs same quarter last year
Source: SEC XBRL filings · latest filing
Show the numbers
| Year | Net income |
|---|---|
| FY25 | −$20.8M |
| FY24 | −$15M |
| FY23 | −$15.4M |
| FY22 | −$14.3M |
| FY21 | −$7.7M |
| FY20 | −$3.6M |
| FY19 | - |